Synthetic Biology News Related News

Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria

– Preclinical studies published in Nature Biotechnology identify key biomarkers of SYNB1618 activity in healthy animals and disease models – – Clinical data expected in 2018 from healthy volunteer cohorts of ongoing Phase 1/ 2a study of SYNB1618; data [...]

Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies

MENLO PARK, Calif., and SAN DIEGO — August 7, 2018 — Teneobio, Inc., a next generation multi-specific antibody therapeutics company, and Poseida Therapeutics, Inc., a San Diego-based clinical-stage company translating best-in-class gene engineering technologies into lifesaving cell therapies, announced today [...]

Yield10 Bioscience Signs Research License Agreement Covering CRISPR-Cas9 Genome-Editing Technology with the Broad Institute and Pioneer

WOBURN, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security, today announced it has signed a non-exclusive research license agreement [...]

Inari Secures $40 Million in Series B Funding to Expand its Development of Transformational Plant Breeding Technologies

● Inari completes a $40M Series B financing round, bringing its total funding to $55M ● Founder Flagship Pioneering is joined by Acre Venture Partners and Alexandria Venture Investments in this financing ● Additional funding will support Inari’s continued investment [...]

News Digest #230 – Opentrons SynBioBetaLive! Today, Pivot Bio’s launch, Partner with P&G.

By | August 12th, 2018|News Digest, Synthetic Biology News|

NSW Health Funds Indee Labs’ First Preclinical Study Into Gene-Modified Cell Therapy Manufacturing for Blood Cancer

This preclinical study will pave the way for biopharmaceutical companies to transition away from using viruses. The aim is to enable gene-modified cell therapy manufacturing with open source biology to provide patients with improved access to curative therapies for blood [...]